Cargando…

Unique volatolomic signatures of TP53 and KRAS in lung cells

BACKGROUND: Volatile organic compounds (VOCs) are potential biomarkers for cancer detection in breath, but it is unclear if they reflect specific mutations. To test this, we have compared human bronchial epithelial cell (HBEC) cell lines carrying the KRAS(V12) mutation, knockdown of TP53 or both wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, M P A, Barash, O, Jeries, R, Peled, N, Ilouze, M, Hyde, R, Marcus, M W, Field, J K, Haick, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453850/ https://www.ncbi.nlm.nih.gov/pubmed/25051409 http://dx.doi.org/10.1038/bjc.2014.411

Ejemplares similares

Analysis of exhaled breath for diagnosing head and neck squamous cell carcinoma: a feasibility study
por: Gruber, M, et al.
Publicado: (2014)

PICT1 regulates TP53 via RPL11 and is involved in gastric cancer progression
por: Uchi, R, et al.
Publicado: (2013)

Differentiation between genetic mutations of breast cancer by breath volatolomics
por: Barash, Orna, et al.
Publicado: (2015)

Breath volatolomics for diagnosing chronic rhinosinusitis
por: Broza, Yoav Y, et al.
Publicado: (2018)

The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer
por: Otto, N, et al.
Publicado: (2012)

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53
por: Meulendijks, D, et al.
Publicado: (2015)

Combined Volatolomics for Monitoring of Human Body Chemistry
por: Broza, Yoav Y., et al.
Publicado: (2014)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Profiling Single Cancer Cells with Volatolomics Approach
por: Serasanambati, Mamatha, et al.
Publicado: (2018)

Volatolomics in healthcare and its advanced detection technology
por: Hu, Wenwen, et al.
Publicado: (2022)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix
por: Kabuubi, P, et al.
Publicado: (2006)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material
por: Bediaga, N G, et al.
Publicado: (2013)

Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors
por: Peng, G, et al.
Publicado: (2010)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

Diagnosis of head-and-neck cancer from exhaled breath
por: Hakim, M, et al.
Publicado: (2011)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
por: Pan, D, et al.
Publicado: (2011)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients
por: Wager, M, et al.
Publicado: (2006)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer
por: Loddo, M, et al.
Publicado: (2009)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
por: Kamoshida, S, et al.
Publicado: (2007)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ce11cactasivrtusbf8u6bo3v4